Arthur C. Santora II - 01 Jan 2022 Form 3 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Medical Officer
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Issuer symbol
ENTX
Transactions as of
01 Jan 2022
Net transactions value
$0
Form type
3
Filing time
14 Jan 2022, 05:56:28 UTC
Next filing
09 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ENTX Stock Option (right to buy) 01 Jan 2022 Ordinary Shares, par value NIS 0.0000769 per share 25,000 $3.97 Direct F1
holding ENTX Stock Option (right to buy) 01 Jan 2022 Ordinary Shares, par value NIS 0.0000769 per share 40,000 $2.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest over a four-year period that commenced on January 17, 2019, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F2 The options vest over a four-year period that commenced on March 16, 2020, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

Remarks:

See Exhibit 24.1 - Power of Attorney